December 10, 2025

The Nephrocare Health IPO is one of the most awaited healthcare offerings in India’s primary market in 2025. As India’s dialysis and renal care demand grows sharply, investors are closely tracking this issue to understand whether it offers meaningful long-term value. Nephrocare Health (widely known for its kidney-care brand NephroPlus) operates one of India’s largest dialysis networks with a strong focus on affordable, accessible renal treatment. With chronic kidney disease (CKD) cases rising every year, this IPO has generated significant interest among retail investors. Below is a complete, SEO-friendly, investor-focused analysis covering IPO dates, price band, financials, business overview, risks, sector outlook, and final recommendation. Nephrocare Health IPO – Key Details Detail Information IPO Opening Date 10 December 2025 IPO Closing Date 12 December 2025 Face Value ₹2 per equity share Price Band ₹438 – ₹460 per share Issue Size ₹871.05 crore Fresh Issue ₹353.41 crore Offer for Sale (OFS) ₹517.64 crore Issue Type Book Built Issue Listing On BSE, NSE Official Website NephroPlus About Nephrocare Health Founded in 2009, Nephrocare Health is one of India’s largest integrated kidney-care and dialysis service networks. The company provides standardized, technologically advanced, and affordable dialysis treatments through its wide presence across major cities and emerging Tier-2/3 locations. Nephrocare follows an asset-light partnership model with hospitals and standalone clinics, ensuring long-term patient engagement and recurring revenue visibility. Business Model Highlights The company’s hub-and-spoke expansion strategy further strengthens scalability while maintaining service quality. Key Management Nephrocare Health – Financial Performance Nephrocare has shown strong revenue growth over the past three years as demand for dialysis services continues to rise. FY Revenue (₹ Cr) Net Profit/Loss (₹ Cr) FY22 ~270 –40 FY23 ~360 –18 FY24 (Estimated) 480+ Near breakeven The company continues to improve operating efficiency as more dialysis centers reach maturity. This has pushed Nephrocare closer to profitability. Objectives of the IPO Proceeds from the fresh issue will be used for: Industry & Sector Outlook – Why This IPO Matters India’s dialysis and renal care market is expanding due to: With over 2 lakh kidney failure cases every year, India’s dialysis requirement continues to surge—benefiting specialized providers like Nephrocare. Strengths Risks & Challenges Competitors Nephrocare competes with: Despite competition, Nephrocare remains among India’s largest standalone dialysis networks. Valuation Overview Final valuation will depend on actual listing price and investor demand. The business is witnessing: Given these factors, analysts expect the IPO to be priced at a moderate-to-premium valuation, typical for high-growth healthcare services companies Conclusion – Should You Apply for the Nephrocare Health IPO? The Nephrocare Health IPO offers a unique opportunity to participate in India’s fast-growing renal care segment. The company’s strong network, recurring revenue model, and scalable operating structure make it an attractive long-term healthcare play. However, since profitability is still evolving, conservative investors should evaluate the IPO valuation carefully. Final Recommendation Why Apply for Long Term? Short-term listing gains may depend on overall market sentiment, but long-term investors focusing on healthcare growth can consider applying. Also Read: Wakefit IPO 2025: Dates, Price Band, Lot Size & Should You Apply?